Alphabet Launches AI Drug Discovery Spin-Off

Alphabet, the parent company of Google, has launched an artificial intelligence (AI) drug discovery firm, Isomorphic Labs, which aims to build on the work of Alphabet’s existing AI subsidiary, DeepMind.

UK-based Isomorphic Labs will apply deep learning software to drug discovery, leveraging DeepMind’s AI software that generates predictive protein structure models.

Demis Hassabis, the CEO and co-founder of DeepMind, is the founder of Isomorphic Labs and will also serve as the company’s CEO.

Alphabet’s other healthcare companies include Verily, a healthcare software firm, and Calico, a biotech specializing in research on aging.